Bioventus 10-Q: Q3 Net Income $6.0M, Nine-Month Operating Cash Flow $49.5M, Debt Cut to $231.8M
BVS sits 70% above its 52-week low of $6.47.
Summary
Bioventus filed its full Q3 10-Q after this morning's release: $142.4M revenue (+2.7%), $6.0M net income, and $49.5M of nine-month operating cash flow that funded $57M of debt prepayments. The $47.0M nine-month profit includes a $26.9M non-cash tax benefit.
Key Events · Earnings and Guidance · BVS
-
Q3 Revenue Up 2.7% to $142.4M
Worldwide net sales rose to $142,442 thousand from $138,651 thousand, led by U.S. Pain Treatments up 4.9% to $62,929 thousand and International up 16.4% to $17,846 thousand.
-
Net Income $6.0M, EPS $0.08
Net income attributable to Bioventus was $5,987 thousand, or $0.08 per diluted share, versus $3,155 thousand ($0.05) a year earlier; Adjusted EBITDA rose to $28,356 thousand from $26,604 thousand.
-
Nine-Month Profit Aided by Tax Benefit
Nine-month net income of $47,010 thousand includes a $26,927 thousand non-cash income tax benefit from releasing part of the deferred tax valuation allowance; the remaining allowance is $20,652 thousand.
-
$57M Discretionary Debt Prepayments
Discretionary prepayments of $22.0M, $20.0M and $15.0M in Q1-Q3 2026 cut gross term loan debt to $231,750 thousand from $296,250 thousand; interest expense fell 42.6% to $12,152 thousand for nine months.
Analysis · BVS · Industrial Applications And Services
The headline numbers were already out this morning, so the 10-Q itself is not a new surprise — but it is the first full look at the quarter's balance sheet and cash flow, and those are the parts that matter for a company in a strategic review. Operating cash flow of $49.5 million over nine months funded $57 million of discretionary term loan prepayments, pulling gross term debt down to $231.8 million from $296.3 million at year-end and cutting interest expense 43% to $12.2 million. Against that, cash fell to $30.7 million from $51.2 million, so liquidity now leans on the $98.4 million of revolver availability rather than the balance sheet. The $47.0 million nine-month profit is flattered by a $26.9 million non-cash tax benefit from releasing part of the valuation allowance — strip that out and the underlying earnings are far more modest. With the sale review still running, the deleveraging is the real story here.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BVS was trading at $11.02 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $6.47 to $15.89. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.